Terms: = Ovarian cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Treatment
581 results:
1. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
Zhan F; Guo Y; He L
J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive analysis of the interaction of antigen presentation during anti-tumour immunity and establishment of AIDPS systems in ovarian cancer.
Sun W; Xu P; Gao K; Lian W; Sun X
J Cell Mol Med; 2024 Apr; 28(8):e18309. PubMed ID: 38613345
[TBL] [Abstract] [Full Text] [Related]
3. Patient-reported outcome measures (PROMs) to personalise follow-up care of ovarian cancer: what do patients think? A qualitative interview study.
Seeratan DD; van Schuylenburch RG; van Lonkhuijzen LRCW; Aarts JWM
Support Care Cancer; 2024 Mar; 32(4):247. PubMed ID: 38528152
[TBL] [Abstract] [Full Text] [Related]
4. Histone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter.
Xiong J; Liang H; Sun X; Gao K
J Cell Mol Med; 2024 Apr; 28(8):e18260. PubMed ID: 38520216
[TBL] [Abstract] [Full Text] [Related]
5. Identification of prognostic factors and construction of nomogram to predict cancer-specific survival for patients with ovarian granulosa cell tumors.
Zhang Y; Zhang Z; Ding X; Zhang K; Dai Y; Cheng W; Luo C
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2046. PubMed ID: 38507268
[TBL] [Abstract] [Full Text] [Related]
6. 5 signature genes revealed by single-cell profiling identified unique immune subtypes affecting the prognosis of ovarian cancer.
Xiang SY; Li QK; Yang Z; Yi Q
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2051-2062. PubMed ID: 38497886
[TBL] [Abstract] [Full Text] [Related]
7. Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1.
Li J; Sun Y; Zhi X; Sun Y; Abudousalamu Z; Lin Q; Li B; Yao L; Chen M
J Ovarian Res; 2024 Mar; 17(1):61. PubMed ID: 38486335
[TBL] [Abstract] [Full Text] [Related]
8. Computational identification of DNA damage-relevant lncRNAs for predicting therapeutic efficacy and clinical outcomes in cancer.
Liu Y; Huang S; Dong G; Hou C; Zhao Y; Zhang D
Comput Biol Med; 2024 Mar; 171():108107. PubMed ID: 38412692
[TBL] [Abstract] [Full Text] [Related]
9. Intraperitoneal Therapy for ovarian cancer - Some Answers, More Questions, and Missed Opportunities.
Yeku OO
NEJM Evid; 2023 May; 2(5):EVIDe2300048. PubMed ID: 38320025
[TBL] [Abstract] [Full Text] [Related]
10. Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients.
Ling L; Li B; Wu H; Zhang K; Li S; Ke B; Zhu Z; Liu T; Liu P; Zhang B
J Gene Med; 2024 Jan; 26(1):e3606. PubMed ID: 38282157
[TBL] [Abstract] [Full Text] [Related]
11. Somatic Genomic and Transcriptomic Characterization of Primary ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
12. Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in ovarian cancer Cells: A Comprehensive Metabolomic Approach.
Kim B; Kim G; Kim H; Song YS; Jung J
Cells; 2024 Jan; 13(2):. PubMed ID: 38247807
[TBL] [Abstract] [Full Text] [Related]
13. An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer.
Zhu K; Ma J; Tian Y; Liu Q; Zhang J
BMC Womens Health; 2024 Jan; 24(1):49. PubMed ID: 38238671
[TBL] [Abstract] [Full Text] [Related]
14. Anoikis related genes may be novel markers associated with prognosis for ovarian cancer.
Yang C; Zhu L; Lin Q
Sci Rep; 2024 Jan; 14(1):1564. PubMed ID: 38238592
[TBL] [Abstract] [Full Text] [Related]
15. The prevention of rectovaginal fistula after rectal cancer surgery by packing with laparoscopic dislocated fat flap containing ovarian vascular pedicle anterior to the anastomotic stoma: a parallel group randomized controlled trial protocol.
Ye DX; Huang SH; Lin Y; Ying-Huang ; Chi P
Trials; 2024 Jan; 25(1):63. PubMed ID: 38233938
[TBL] [Abstract] [Full Text] [Related]
16. Identification and validation of anoikis-related lncRNAs for prognostic significance and immune microenvironment characterization in ovarian cancer.
Cao L; Zhang S; Peng H; Lin Y; Xi Z; Lin W; Guo J; Wu G; Yu F; Zhang H; Ye H
Aging (Albany NY); 2024 Jan; 16(2):1463-1483. PubMed ID: 38226979
[TBL] [Abstract] [Full Text] [Related]
17. Construction of monocyte-related prognosis model based on comprehensive analysis of bulk RNA-seq and single-cell RNA-seq in high-grade serous ovarian cancer.
Xu Y; Tan S; Huang W; Wang YX
Medicine (Baltimore); 2023 Dec; 102(50):e36548. PubMed ID: 38115318
[TBL] [Abstract] [Full Text] [Related]
18. Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.
Yuan J; Li X; Wang F; Liu H; Guan W; Xu G
Exp Biol Med (Maywood); 2023 Dec; 248(23):2198-2209. PubMed ID: 38084732
[TBL] [Abstract] [Full Text] [Related]
19. Identification of a cancer associated fibroblasts-related index to predict prognosis and immune landscape in ovarian cancer.
Ye Y; Zhang S; Jiang Y; Huang Y; Wang G; Zhang M; Gui Z; Wu Y; Bian G; Li P; Zhang M
Sci Rep; 2023 Dec; 13(1):21565. PubMed ID: 38057405
[TBL] [Abstract] [Full Text] [Related]
20. ovarian cancer disease burden decreased in the United States from 1975 to 2018: A joinpoint and age-period-cohort analysis.
He J; Hu Q
Medicine (Baltimore); 2023 Dec; 102(48):e36029. PubMed ID: 38050303
[TBL] [Abstract] [Full Text] [Related]
[Next]
